LN229 Orthotopic Mouse Model Service for Brain Cancer

The LN229 orthotopic mouse model for brain cancer provides a human glioblastoma xenograft platform distinguished by its diffusive growth pattern, perivascular migratory capacity, and propensity to polarize resident microglia toward an M2 tumor-supportive phenotype—features that closely mirror the invasive biology of clinical high-grade glioma. Alfa Cytology delivers this specialized orthotopic model service with integrated capabilities spanning stereotactic intracranial implantation into immunodeficient hosts, longitudinal MRI and bioluminescence monitoring, immune microenvironment phenotyping, and comprehensive endpoint analysis—empowering researchers to dissect glioma invasion dynamics and accelerate preclinical therapeutic development with precision.

Overview of LN229 Orthotopic Mouse Model for Brain Cancer

The LN229 cell line was established in 1979 from a right frontal parieto-occipital glioblastoma resected from a 53-year-old male patient and is catalogued as ATCC CRL-2611. Exhibiting epithelial-like morphology and adherent growth kinetics, LN229 possesses one of the highest proliferation rates among commonly used glioblastoma lines, coupled with a robust colony-forming capacity that underscores its tumorigenic potential. Genetically, the line is characterized by a mutant TP53 allele, a wild-type PTEN gene, and homozygous deletions of the p16 and p14ARF tumor suppressor loci—an alteration pattern that sustains unchecked cell cycle progression and attenuates apoptotic signaling. The cells also harbor an activating hTERT promoter mutation with concomitant upregulation of telomerase transcript levels, conferring replicative immortality. In two-dimensional culture, LN229 displays a relatively lower migratory velocity compared to some aggressive counterparts, yet its intrinsic biology unfolds very differently within the brain parenchyma.

Fig 1. Tumor growth in two GBM cell lines in orthotopic xenograft mouse models. (Han, Ji-hun, et al., 2020)

When orthotopically implanted into immunodeficient hosts, LN229 cells exhibit a distinctly diffusive growth pattern that diverges sharply from the compact, demarcated margins seen in several other glioblastoma xenograft models. Tumor cells disperse widely from the primary mass, frequently migrating along blood vessel tracks into remote brain regions and occasionally extending beyond the meninges—a perivascular invasive behavior that recapitulates a hallmark of human glioblastoma dissemination. This diffusive nature is partly driven by elevated CXCR4-STAT3 axis signaling, which orchestrates tumor cell trafficking toward endothelial structures. Moreover, LN229-bearing tumors accumulate substantial numbers of resident microglia and peripheral macrophages in peritumoral zones, with the glioma cells actively skewing these myeloid populations toward an M2-like, CD206-positive, immunosuppressive state while suppressing M1-type IL-1β responses. Consequently, the LN229 orthotopic model is particularly suited for studying glioma invasion mechanisms, tumor-stromal crosstalk, perivascular niche targeting, and strategies aimed at reprogramming the glioma immune microenvironment.

Cell Line Information: LN229

The table below presents comprehensive characterization data for the LN229 human glioblastoma cell line to support model selection and experimental design for preclinical brain cancer studies.

Our Services

Alfa Cytology provides a comprehensive LN229 orthotopic mouse model service tailored to the demands of diffusive glioblastoma preclinical research, encompassing STR-authenticated cell expansion, precision stereotactic intracranial implantation into nude or NSG hosts, longitudinal MRI and bioluminescence tumor tracking, perivascular invasion mapping, and detailed immune microenvironment phenotyping at endpoint. Our neuro-oncology team ensures reproducible diffusive tumor kinetics, stringent quality control, and flexible study architectures that integrate seamlessly with your therapeutic development objectives.

Workflow of LN229 Orthotopic Mouse Model Construction

Construction of the LN229 orthotopic glioblastoma model employs a refined stereotactic neurosurgical protocol optimized for capturing the diffusive, perivascular invasive biology of this human glioblastoma line. The workflow integrates cell quality verification, precision intracranial delivery, and longitudinal multimodal monitoring to generate robust, publication-quality preclinical datasets.

1. Cell Line Authentication and Expansion: LN229 cells are authenticated by human STR profiling and expanded in high-glucose DMEM complete medium to ensure epithelial-like morphology integrity, genetic stability, and viability >95% prior to surgical preparation.
2. Luciferase Labeling (Optional): For longitudinal non-invasive monitoring of diffusive tumor spread, LN229 cells are transduced with a luciferase-GFP construct and selected to generate stable pools with consistent bioluminescent and fluorescent signal output.
3. Host Selection and Acclimatization: Immunodeficient mice—typically female athymic BALB/c nude mice or NSG mice aged 6–8 weeks—are acclimatized for at least one week with health screening and baseline body weight recording to minimize inter-animal variability.
4. Anesthesia and Surgical Preparation: Mice are anesthetized with isoflurane (induction 2.5%, maintenance 1–2%) or pentobarbital sodium; the head is shaved, disinfected with alternating betadine and alcohol swabs, and secured in a stereotactic frame with a thermoregulated heating pad.
5. Stereotactic Coordinate Calibration: Bregma and lambda are identified after gentle periosteal reflection; a 0.9 mm burr hole is drilled at coordinates 2 mm lateral and 2 mm posterior to bregma, targeting the right striatum, with the dura mater left intact to minimize cortical trauma.
6. Intracranial Cell Injection: A Hamilton syringe loaded with 3–5 µL of LN229 cell suspension (1 × 10⁵ viable cells in sterile PBS) is inserted to a depth of 3–3.5 mm, and cells are slowly injected at a controlled rate; the needle is held in place for 3–5 minutes to prevent reflux and backflow along the injection tract.
7. Cranial Closure and Postoperative Care: The burr hole is sealed with bone wax or sterile collagen sponge, the scalp incision is closed with surgical adhesive or sutures, and mice are recovered on a heated pad with analgesic support per institutional animal care guidelines.
8. Tumor Establishment Verification: Tumor engraftment is confirmed 7–14 days post-implantation via bioluminescence imaging (for luciferase-expressing lines) or T2-weighted MRI; mice displaying confirmed tumor signals are randomized into vehicle and treatment cohorts.
9. Longitudinal Monitoring and In-Life Assessment: Tumor burden and diffusive spread are tracked biweekly via bioluminescence imaging and T2-weighted MRI; concurrent recording of body weight, neurological deficit scoring, and overall clinical condition enables early detection of treatment-related toxicities and peritumoral edema.
10. Treatment Administration: Investigational agents—including CXCR4 antagonists, STAT3 inhibitors, microglia reprogramming agents, temozolomide analogs, targeted small molecules, or combination regimens—are administered according to protocol-defined schedules via intravenous, intraperitoneal, oral, or intracranial routes as appropriate.
11. Necropsy and Tissue Procurement: At study endpoint, brains are harvested en bloc, photographed, and sectioned coronally into serial slices; tumor dimensions and dispersal zones are mapped, and tissue aliquots are allocated for formalin-fixed paraffin embedding, snap-freezing, and downstream molecular analysis.
12. Histopathological and Microenvironment Characterization: Tumor sections undergo H&E staining, IHC for Ki-67, CD31, CXCR4, phospho-STAT3, CD206, IL-1β, and Iba1, alongside immunofluorescence for GFP-labeled tumor cells and CD31-positive vasculature to quantify perivascular invasion and microglia polarization states.
13. Data Integration and Reporting: All imaging, survival, biometric, and molecular data are compiled into a comprehensive study report with tumor growth curves, dispersal zone quantification, Kaplan-Meier survival analyses, neurological scoring summaries, and pharmacodynamic interpretations suitable for regulatory or publication use.

Fig 2. LN229 Orthotopic Mouse Model construction workflow.

Case Study-LN229 Orthotopic Mouse Model Development

In a representative preclinical engagement, the LN229 orthotopic glioblastoma model was established in immunodeficient mice with reproducible diffusive tumor take and progressive perivascular infiltration extending beyond the primary mass into remote brain zones over an 8-week treatment window. Treatment cohorts receiving a CXCR4 antagonist demonstrated reduced dispersal of tumor cells along CD31-positive vasculature compared to vehicle controls, accompanied by decreased phospho-STAT3 immunoreactivity in peritumoral regions. A parallel combination arm pairing the CXCR4 inhibitor with a microglia-repolarizing agent showed enhanced therapeutic synergy, with improved containment of diffusive tumor margins and increased M1-type IL-1β-positive microglia accumulation at the tumor boundary. Detailed quantitative datasets—including longitudinal MRI tumor volume measurements, bioluminescence dispersal indices, neurological scoring trends, and microglia polarization profiling data—are available for review; please reach out to our scientific team to discuss how these findings can inform your specific glioblastoma therapeutic strategy.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your LN229 orthotopic model program provides access to a diffusive glioblastoma-focused service platform with deep expertise in perivascular invasion biology, microglia phenotyping, and neurosurgical precision.

• Established proficiency with diffusive human glioblastoma xenografts and optimized stereotactic protocols that yield consistent LN229 intracranial engraftment with authentic perivascular migratory behavior.
• Integrated longitudinal imaging infrastructure spanning T2-weighted MRI and bioluminescence for real-time tracking of diffusive tumor spread and early pharmacodynamic readouts.
• Specialized tumor-microenvironment analysis capabilities including perivascular invasion mapping, CXCR4-STAT3 pathway profiling, and M1/M2 microglia polarization quantification.
• Expertise in evaluating agents targeting glioma dispersal, perivascular niche disruption, and immune microenvironment reprogramming within a physiologically relevant brain context.
• Flexible study designs supporting monotherapy, combination, sequential, and biomarker-stratified arms tailored to your compound mechanism and regulatory requirements.
• Rigorous cell authentication, health surveillance, and GLP-aligned documentation practices that uphold data integrity for IND-enabling and peer-review standards.

Contact Us

To explore how the LN229 orthotopic mouse model can advance your diffusive glioblastoma preclinical program, we invite you to reach out to us for a confidential scientific consultation. Our neuro-oncology specialists will evaluate your therapeutic target, propose a customized study design leveraging the unique perivascular invasive and microglia-polarizing features of this human glioblastoma xenograft, and outline a clear roadmap to generating the high-quality data your discovery team requires. Contact us today and let Alfa Cytology drive your next preclinical milestone in brain cancer research.

For research use only. Not intended for any clinical use.